Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

27P - Quantitative detection of plasma extracellular vesicles in early and metastatic breast cancer patients using SiMoA technology

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Marta Truffi

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101218-101218. 10.1016/esmoop/esmoop101218

Authors

M. Truffi1, S. Albasini1, F. Piccotti1, L. Signati2, A. Faiulo1, F. Sottotetti1, I. Tallarico1, B. Tagliaferri1, F. Corsi1

Author affiliations

  • 1 IRCCS Pavia - Istituti Clinici Scientifici Maugeri, Pavia/IT
  • 2 Università degli Studi di Milano, Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 27P

Background

Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from a cell. Initially regarded as waste products, nowadays EVs draw interest due to their role in intercellular communications. In breast cancer (BC), EVs play a role in the interplay between cancer cells and tumor microenvironment, and in the preparation of pre-metastatic niche in distant organs. Since they are present in many biofluids, EVs could have an exciting potential as liquid biopsy-derived biomarkers. Aim of this study was to assess EVs plasma levels in patients affected by early and metastatic BC using Single Molecule Array (SiMoA), a digital ELISA able to quantify low concentrations of target molecules.

Methods

SiMoA assays were developed based on a bead-immune separation of EVs followed by the direct quantification of the target on top of the magnetic beads. As target we used well know markers of EVs, i.e. CD9 and CD81, while the beads were functionalized to capture CD63, another EV-associated tetraspanin. Patients affected by early (n=56) and metastatic BC (n=44) were prospectively recruited at Istituti Clinici Scientifici Maugeri (Pavia, Italy). A control group of healthy subjects was also enrolled. For each patient a blood sample was collected and plasma was isolated for analysis.

Results

The anti-CD63/anti-CD9 and anti-CD63/anti-CD81 SiMoA assays allowed the analysis of EVs directly in unprocessed plasma with good reproducibility performance. EVs levels were significantly higher in early BC than healthy controls by both assays. Metastatic BC, instead, showed lower levels of EVs as compared to healthy controls and early BC by both assays. By calculating the fraction of CD81-expressing EVs related to the amount of those expressing CD9 we observed that EVs from metastatic BC samples were enriched in CD81 as compared to healthy and early BC.

Conclusions

EVs levels measured by SiMoA increased in early BC and decreased in metastatic BC, suggesting that EVs reflect functional changes occurring during BC progression. As perspective, the identification of more specific markers will help to quantify subpopulation of EVs associated to different BC stages, improving early diagnosis and favoring timely intervention.

Legal entity responsible for the study

Prof. Fabio Corsi.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.